SciTech Development Revenue
Pharmaceutical Manufacturing • 
Grosse Pointe Farms, Michigan, United States • 11-20 Employees
SciTech Development revenue & valuation
| Annual revenue | $941,105 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $3,100,000 |
| Total funding | $11,640,000 |
Key Contacts at SciTech Development
Earle Holsapple
Founder And Ceo
Phil Robertson
Director Of Business Development
Company overview
| Headquarters | 281 Kercheval Avenue, Grosse Pointe Farms, MI 48236, US |
| Phone number | +104234048 |
| Websites | |
| NAICS | 3254 |
| Keywords | Bioavailability, Investment, Partnering, Immunotherapy, Cancer, Drug Delivery, SDP, Drug, Lymphoma, St-001, Scitech, Combination, Fenretinide, Phospholipid, Small Cell Lung Cancer, Standalone, T-Cell, Nanofenretinide |
| Employees | 11-20 |
| Socials |
SciTech Development Email Formats
SciTech Development uses 2 email formats. The most common is {first name} (e.g., john@scitechdevelopment.com), used 50% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@scitechdevelopment.com | 50% |
{first name}.{last name} | john.doe@scitechdevelopment.com | 50% |
About SciTech Development
SciTech Development is a clinical-stage, oncology-focused pharmaceutical company. Through innovative science and advanced nanotechnology, we’ve engineered ST-001 nanoFenretinide (ST-001)—a patented, new drug that combines a potent anticancer agent with a novel nanoparticle delivery system. ST-001 is now in clinical trials for T-cell non-Hodgkin lymphoma (T-cell NHL). Exceptional preliminary data indicates successful drug delivery to targeted tissue, addresses dug bioavailability, reduces triglyceride toxicity, and has been proven safe to enhance therapeutic effectiveness. Guided by previous fenretinide studies, ST-001 may have potential across 15+ additional cancers—including lung, leukemia, head & neck, brain, ovarian, cervical, and pancreatic—either as a standalone therapy, a complementary agent, or in combination with chemotherapy to address critical unmet needs. The FDA has cleared a second IND, enabling our upcoming small-cell lung cancer (SCLC) trial. Our scalable drug development and nanomanufacturing is built to move ST-001 efficiently from lab to clinic. With $16M+ raised to date, we’re actively securing additional capital to accelerate development while deepening our commitment to innovation and strategic partnerships. Note: ST-001 is investigational and not yet FDA approved for commercial use.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
SciTech Development has 5 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore SciTech Development's funding history, including investment rounds, total capital raised, and key backers.
Italy
Denmark
Spain
AustraliaFrequently asked questions
4.8
40,000 users
